When was AnaCardio founded?

AnaCardio was founded in 2017 and raised its 1st funding round 4 years after it was founded.

Where is AnaCardio located?

AnaCardio is headquartered in Sweden.

How many employees does AnaCardio have?

As of Aug 31, 2026, the latest employee count at AnaCardio is 26.

Is AnaCardio a funded company?

AnaCardio is a funded company, having raised a total of $107M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jun 17, 2021.

When was the latest funding round of AnaCardio?

AnaCardio's latest funding was a $***** Series B round on Sep 29, 2026, with participation from 5 investors.

Where does AnaCardio rank among its competitors?

AnaCardio ranks 4th amongst 51 active competitors, of which 21 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Secretome Therapeutics, which secured $30M in May, 2026.

Who are the top competitors of AnaCardio?

AnaCardio's top competitors include AskBio, Mission Therapeutics and Nuevocor. Among them, AnaCardio secured the most recent funding round in September, 2026.

AnaCardio - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of drugs for heart failure treatment. The company has developed an intravenous endogenous peptide hormone that improves cardiac contractility and clinical outcomes in heart failure.

Key Metrics

Founded Year

2017

Location

Sweden

Stage

Series B

Total Funding

$107M in 5 rounds

Latest Funding Round

Series B, Sep 29, 2026, $*****

Investors

Karolinska Development & 10 more

Ranked

4^th among 51 active competitors

Employee Count

26 as on Aug 31, 2026

Similar Companies

AskBio & 53 more

View AnaCardio's full profile

AnaCardio has raised a total funding of $107M over 5 rounds. Its first funding round was on Jun 17, 2021. Its latest funding round was a Series B round on Sep 29, 2026 for $*****. 5 investors participated in its latest round. AnaCardio has 8 institutional investors and 3 angel investors.

Here is the list of recent funding rounds of AnaCardio:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 29, 2026	7667500	Series B	6868854	5441570	2532094	5508477
Jan 09, 2025	3498689	Series A	8760542	3377107	5243284	Flerie & 3 more
Sep 07, 2022	4112529	Series A	7715969	5932163	Flerie & 2 more	Karolinska Development & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of AnaCardio's funding rounds and investors

The founders of AnaCardio is Lars Lund.

Here are the details of AnaCardio's key team members:

Lars Lund: Founder of AnaCardio.
Contact Info: 1 email address

View details of AnaCardio's Founder profiles and Board Members

AnaCardio's employee count trend

AnaCardio has 26 employees as of Aug 26. Here is AnaCardio's employee count trend over the years:

Uncover AnaCardio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of AnaCardio include AskBio, Mission Therapeutics and Nuevocor. Here is the list of Top 10 competitors of AnaCardio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	AskBio 2001, Durham (United States), Acquired	Developer of AAV technologies for treating genetic and complex disorders	$235M	Vida Ventures, TPG & 4 others	68/100
2nd	Mission Therapeutics 2011, Cambridge (United Kingdom), Series D	Developer of small molecule inhibitors targeting specific disease associated enzymes	$192M	Sofinnova Partners, Pfizer Venture Investments ... & 46 others	64/100
3rd	Nuevocor 2021, Singapore (Singapore), Series B	Developer of genetic medicines for treating rare heart muscle conditions	$80.6M	Kurma Partners, Boehringer Ingelheim Venture Fund ... & 7 others	62/100
4th	AnaCardio 2017, Sweden, Series B	Developer of drugs for heart failure treatment	$107M	Industrifonden, Pureos Bioventures & 9 others	62/100
5th	Secretome Therapeutics 2018, Dallas (United States), Series A	Developer of cell-based therapies for multiple diseases	$52.2M	RA Capital Management, Parent Project Muscular Dystrophy ... & 2 others	61/100
6th	Juvenescence 2017, Dublin (Ireland), Series B	Provider of proprietary ketone ester-based therapeutic drink for age-related disorders and metabolic health	$290M	Foresite Capital, Grok Ventures & 10 others	59/100
7th	Tenax Therapeutics 1967, Morrisville (United States), Public	Developer of therapeutics to address cardiovascular and pulmonary diseases	-	RTW Investments, Westwicke & 1 others	52/100
8th	SparkBioPharma Seoul (South Korea), Series C	Developer of small-molecule therapeutics for multiple disorders	$42.5M	Plexus Partners, Emford Equity & 10 others	51/100
9th	Heartseed 2015, Shinjuku City (Japan), Public	Developer of myocardial regenerative medicine for treating heart diseases	$76.7M	Sumitomo Mitsui Trust Holdings, SBI Group ... & 18 others	47/100
10th	SmartCella 2014, Stockholm (Sweden), Unfunded	Developer of cell therapy and delivery device for cardiac diseases	-	-	45/100